Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report)’s share price traded up 4.4% during mid-day trading on Friday . The stock traded as high as $18.86 and last traded at $18.30. 6,240 shares were traded during trading, a decline of 77% from the average session volume of 26,930 shares. The stock had previously closed at $17.53.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the company. UBS Group raised their target price on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, January 27th. William Blair restated an “outperform” rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research note on Wednesday, March 12th.
Check Out Our Latest Research Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Price Performance
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- What is a SEC Filing?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- How to Invest in Biotech Stocks
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.